Phase I dose de-escalation trial of α-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 303-310

  Mitchell, Michele Follen ^a,b   Tortolero Luna, Guillermo ^a   Lee, J Jack ^a   Hittelman, Walter N ^a   Lotan, Reuben ^a   Wharton, J Taylor ^a   Hong, Waun K ^a   Nishioka, Kenji ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; EFLORNITHINE; POLYAMINE; SPERMIDINE; SPERMINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; FEMALE; HUMAN; MALAISE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMATITIS; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA IN SITU; VERTIGO;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; ARGININE; BIOGENIC POLYAMINES; CERVICAL INTRAEPITHELIAL NEOPLASIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EFLORNITHINE; ENZYME INHIBITORS; FEMALE; HUMANS; ORNITHINE; ORNITHINE DECARBOXYLASE; UTERINE CERVICAL NEOPLASMS;

EID: 0031889260     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Brinton, L. A. Epidemiology of cervical cancer-Overview. In: N. Muñoz, F. Bosch, K. V. Shah, and Meheus A (eds.), The Epidemiology of Human Papillomavirus and Cervical Cancer, pp. 3-23. IARC Sci. Publ. No. 119. Lyon, France: IARC, 1992.
2. Parkin, D. M., Pisani, P., and Ferlay, J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int. J. Cancer, 54: 594-606, 1993.
3. American Cancer Society. Cancer Facts and Figures, p. 7. Atlanta: American Cancer Society, 1996.
4. Daly, M. B. The chemoprevention of cancer: directions for the future. Cancer Epidemiol. Biomark. Prev., 2: 509-512, 1993.
5. Kelloff, G. J., Boone, C. W., Steele, V. E., Crowell, J. A., Lubet, R., and Sigman, C. C. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res., 52 (Suppl.): 2015s-2024s, 1994.
6. Lippman, S. M., Hong, W. K., and Benner, S. E. The chemoprevention of cancer. In: P. Greenwald, B. S. Kramer, and D. L. Weed (eds.), Cancer Prevention and Control, pp. 329-351. New York: Marcel Dekker, Inc, 1995.
7. Marton, L. J., and Pegg, A. E. Polyamines as targets for therapeutic intervention. Annu. Rev. Toxicol., 35: 55-91, 1995.
8. Verma, A. K., and Boutwell, R. K. Inhibition of carcinogenesis by inhibitors of putrescine biosynthesis. In: P. P. McCann, A. E. Pegg, and A. Sjoerdsma (eds.), Inhibition of Polyamine Metabolism, Biological Significance and Basis for New Therapies, pp. 249-258. Orlando, FL: Academic Press, 1987.
9. Auvinen, M., Paasinen, A., Andersson, L. C., and Holtta, E. Orinthine decarboxylase activity is critical for cell transformation. Nature (Lond.), 360: 355-358, 1992.
10. Nishioka, K. Introduction to polyamines. In: K. Nishioka (ed.), Polyamines in Cancer: Basic Mechanisms and Clinical Approaches, pp. 1-5. Austin, TX: R. G. Landes Co., 1996.
11. Jasnis, M. A., Klein, S., Monte, M., Davel, L., Sacerdote de Lustig, E., and Algranati, I. D. Polyamines prevent DFMO-mediated angiogenesis. Cancer Lett., 79: 39-43, 1994.
12. Nishioka, K., Mitchell, M. F., and Ajani, J. A. Clinical studies of polyamines and their antimetabolites. In: K. Nishioka (ed.), Polyamines in Cancer: Basic Mechanisms and Clinical Approaches, pp. 251-278. Austin, TX: R. G. Landes Co., 1996.
13. Chemoprevention Branch (DCPC), National Cancer Institute. Eflornithine HC1 (DFMO): Investigator's Brochure, 1996.
14. Love, R. R., Carbone, P. P., Verma, A. K., Gilmore, D., Carey, P., Tutsch, K. D., Pomplun, M., and Wilding, G. Randomized Phase I chemoprevention dose-seeking study of α-difluoromethylornithine. J. Natl. Cancer Inst., 85: 732-736, 1993.
15. Creaven, P. J., Pendyala, L., and Petrelli, N. J. Evaluation of α-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in human. Cancer Epidemiol. Biomark. Prev., 2: 243-247, 1993.
16. Meyskens, F. L., Emerson, S. S., Pelot, D., Meshkinpour, H., Shassetz, L. R., Einspahr, J., Alberts, D. S., and Gerner, E. W. Dose de-escalation chemoprevention trial of α-difluoromethylomithine in patients with colon polyps. J. Natl. Cancer Inst., 86: 1122-1130, 1994.
17. Hixson, L. J., Garewal, H. S., McGee, D. L., Sloan, D., Fennerty, M. B., Sampliner, R. E., and Gerner, E. W. Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol. Biomark. Prev., 2: 369-374, 1993.
18. Pendyala, L., Creaven, P. J., and Porter, C. W. Urinary and erthrocyte polyamines during the evaluation of oral α-difluoromethylornithine in a Phase I chemoprevention trial clinical trial. Cancer Epidemiol. Biomark. Prev., 2: 235-241, 1993.
19. Loprinzi, C. L., Messing, E. M., O'Fallon, J. R., Poon, M. A., Love, R. R., Quella, S. K., Trump, D. L., Morton, R. F., and Novotny, P. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Cancer Epidemiol. Biomark. Prev., 5: 371-374, 1996.
20. Grove, J., Fozard, J. R., and Mamont, P. S. Assay of α-difluoromethylornithine in body fluids and tissues by automated amino acid analysis. J. Chromatogr., 223: 409-416, 1981.
21. Nishioka, K., Melgarejo, A. B., Lyon, R. R., and Mitchell, M. F. Polyamines as biomarkers of cervical intraepithelial neoplasia. J. Cell. Biochem., 23 (Suppl.): 87-95, 1995.
22. Wang, W., Liu, L. Q., and Higuchi, C. M. Mucosal polyamine measurements and colorectal cancer risk. J. Cell. Biochem., 63: 252-257, 1996.
23. Boyle, J. O., Meyskens, F. L., Garewal, H. S., and Gerner, E. W. Polyamine content in rectal an buccal mucosae in humans treated with oral difluoromethylornithine. Cancer Epidemiol. Biomark. Prev., 1: 131-135, 1992.